Basel, Basel, Switzerland
I am a protein biochemist (Dr. rer. nat.) holding a position as Section Leader at Roche (Basel) responsible for analytical development and quality control of biopharmaceuticals during clinical trials (IND) and licensing (BLA/MAA). After studying Molecular Biotechnology at TU München, I did my PhD at the Biochemistry Center of Heidelberg in the field of eukaryotic ribosome biogenesis. Before joining Roche in 2018, I worked as research scientist (drug discovery and validation) for Immuno-Oncology biotech Immunocore Ltd. in Oxfordshire (UK).
- Direct technical and personnel management of a team of approximately 30, ensuring development, training, compliance, workload organization, resource allocation, and continuous improvement. - Mentor and coach teams on early- and late-stage biologics portfolio programs, ensuring efficient project timelines and successful licensing outcomes (IMA). - Drive the development and implementation of new technologies to enhance analytical and operational performance. - Develop and implement strategies and goals aligned with organizational priorities and the needs of product stakeholders.
Our department within Roche's Pharma division is responsible for biochemical and biophysical Analytical Development, Quality Control and Compliance for Biopharmaceuticals from Investigational New Drug (IND/IMPD) to licensing&Launch (BLA/MAA). Our activities include stability & release testing of drug substance (GMP), in-process control testing, method development & validation, equipment qualification, development of analytical control strategy, (p)CQA assessment, variant characterization, method transfer, analytical comparability assessment, process development & validation and implementation of novel technologies into our method repertoire. Responsibilities/Roles: - Drug Substance (DS) analytical Lead for Early and Late Stage projects - Analytical Tech-Transfer Lead - QbD (Quality by Design) Control Strategy Team Lead for Europe - AET (Analytical Expert Team) member for Charge Heterogeneity methods
Immunocore Ltd. is one of the world’s leading T cell receptor (TCR) company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases - utilising their pioneering soluble TCR technology platform. I was working in Immunocore's department of Infectious Diseases (ID), where I was identifying, validating, and engineering suitable immune-activating TCR-based reagents that are subject to preclinical and clinical assessment.
Lab of Prof. Dr. Ed Hurt. Title: "Deciphering eukaryotic ribosome biogenesis: Structure and function of the 90S pre-ribosome providing unprecedented insight into the birth of the eukaryotic small ribosomal subunit (40S)". Additional tasks: Supervision of Master's and Bachelor's students.
Master’s Thesis in eukaryotic Gene Targeting (Module of Molecular Medicine), lab of Prof. Angelika Schnieke. Project: “Pancreas-specific expression of Cre recombinase by successful and efficient targeting of the putative porcine ROSA26 locus”.
2-month Protein Engineering Internship in the team of Prof. Dr. Arne Skerra: “Engineering of a bacterial omega-transaminase for industrial diamine production”.